Oncolytics Biotech Inc.
ONC.TO
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.06% | -26.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.43% | -19.09% | |||
| Operating Income | 15.43% | 19.09% | |||
| Income Before Tax | 5.69% | 18.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.37% | 18.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.37% | 18.64% | |||
| EBIT | 15.43% | 19.09% | |||
| EBITDA | 15.49% | 19.29% | |||
| EPS Basic | 11.07% | 25.34% | |||
| Normalized Basic EPS | 12.21% | 25.22% | |||
| EPS Diluted | 11.07% | 25.34% | |||
| Normalized Diluted EPS | 12.21% | 25.22% | |||
| Average Basic Shares Outstanding | 7.52% | 9.10% | |||
| Average Diluted Shares Outstanding | 7.52% | 9.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||